Equillium Inc
NASDAQ:EQ
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Equillium Inc
Cash from Investing Activities
Equillium Inc
Cash from Investing Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Investing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Equillium Inc
NASDAQ:EQ
|
Cash from Investing Activities
$4.5m
|
CAGR 3-Years
-38%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Cash from Investing Activities
-$6.6B
|
CAGR 3-Years
-120%
|
CAGR 5-Years
29%
|
CAGR 10-Years
6%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cash from Investing Activities
-$4.8B
|
CAGR 3-Years
-25%
|
CAGR 5-Years
20%
|
CAGR 10-Years
9%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Cash from Investing Activities
-$1.9B
|
CAGR 3-Years
31%
|
CAGR 5-Years
18%
|
CAGR 10-Years
10%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cash from Investing Activities
-$945.4m
|
CAGR 3-Years
-43%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cash from Investing Activities
-$629.1m
|
CAGR 3-Years
45%
|
CAGR 5-Years
-55%
|
CAGR 10-Years
4%
|
|
Equillium Inc
Glance View
Equillium, Inc. engages in the development of products for severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company is headquartered in La Jolla, California and currently employs 45 full-time employees. The company went IPO on 2018-10-12. The firm develops products to treat severe autoimmune and inflammatory disorders with unmet medical needs. The firm's initial product candidate, itolizumab (EQ001), is a clinical-stage, monoclonal antibody that selectively targets CD6, a co-stimulatory receptor differentially expressed on subsets of pro-inflammatory T cells. The firm's CD6 plays a central role in the modulation of effector T cell, or Teff cell, activity and trafficking. Activated Teff cells drive several immuno-inflammatory diseases across therapeutic areas including transplant science, systemic autoimmunity, pulmonary, neurologic, gastrointestinal, renal, vascular, ophthalmic and dermatologic disorders. The company also provides structured-domain peptides, including BNZ-1 and BNZ-2, entirely in-house from product discovery platform. These lead product candidates are multi-specific inhibitors that targets range of immuno-inflammatory indication.
See Also
What is Equillium Inc's Cash from Investing Activities?
Cash from Investing Activities
4.5m
USD
Based on the financial report for Dec 31, 2025, Equillium Inc's Cash from Investing Activities amounts to 4.5m USD.
What is Equillium Inc's Cash from Investing Activities growth rate?
Cash from Investing Activities CAGR 3Y
-38%
Over the last year, the Cash from Investing Activities growth was -68%. The average annual Cash from Investing Activities growth rates for Equillium Inc have been -38% over the past three years .
